Vivoryon Therapeutics N.V. (LON:0R3M)

London flag London · Delayed Price · Currency is GBP · Price in EUR
1.698
+0.010 (0.59%)
At close: Jun 6, 2025
-19.14%
Market Cap 35.56M
Revenue (ttm) n/a
Net Income (ttm) -17.01M
Shares Out n/a
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 62
Average Volume 252
Open 1.700
Previous Close 1.688
Day's Range 1.698 - 1.748
52-Week Range 1.350 - 2.960
Beta n/a
RSI 26.97
Earnings Date Jun 17, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange London Stock Exchange
Ticker Symbol 0R3M
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.